RxDoctor Payments Data

Suzanne Abraham, DPM

Podiatrist · Phoenix, AZNPI 1982655957

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,319 of the $3,519 with a category attached, or 65.9%. 23 manufacturers reported payments, led by Impactortho, Inc. at 35.0% of the total. Reporting peaked in 2022 at $1,432 and has fallen 69.3% since, to $439 in 2025.

$3,519in general payments, 2019–2025

Across 116 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impactortho, Inc.$1K
  • Organogenesis Inc.$430
  • Stryker$395
  • Orthofix Medical, Inc.$238
  • AbbVie$195
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$181
  • plus $850 from 17 others

What the payments were for

  • Food & beverage$2,31966%
  • Education$1,20034%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,519 in reported general payments places this provider in the 80th percentile of 151 podiatrist providers in Arizona.

See all podiatrist providers in Arizona

Medicare billing

Part B allowed, 2024
$184,977
Medicare patients
450
Services billed
1,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole16$21,247
Ketoconazole50$1,607
SsdSilver Sulfadiazine79$496
Cephalexin30$258
Clindamycin Hcl14$236
Triamcinolone Acetonide15$200
Doxycycline Monohydrate13$158
Silver Sulfadiazine19$147
Mupirocin19$147
Terbinafine Hcl12$70
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$181$21,24716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 151 podiatrist providers in Arizona.

Other podiatrist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →